Showing results (31-40 of 108) with videos related to

Sort By:
Pageof 11
Bulletin Du Cancer|October 9, 2014
[Bevacizumab and taxanes in the first-line treatment of metastatic breast cancer : overall survival and subgroup analyses of the ATHENA study in France]Jean-Yves Pierga, Rémy Delva, Xavier Pivot, et al.
Journal of Gastrointestinal Oncology|April 29, 2014
The influence of radiation therapy dose escalation on overall survival in unresectable pancreatic adenocarcinomaWilliam A Hall, Lauren E Colbert, Dana Nickleach, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2019
Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU StudyOlivier Colomban, Michel Tod, Alexandra Leary, et al.
BMC Cancer|December 19, 2012
Can treatment with Cocculine improve the control of chemotherapy-induced emesis in early breast cancer patients? A randomized, multi-centered, double-blind, placebo-controlled Phase III trialDavid Pérol, Jocelyne Provençal, Anne-Claire Hardy-Bessard, et al.
Bulletin Du Cancer|July 6, 2011
[Node negative breast cancer. Beyond international consensus: a pragmatic approach]Frédérique Penault-Llorca, David Coeffic, Thierry Delozier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2005
Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancerStéphane Oudard, Eugeniu Banu, Philippe Beuzeboc, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 8, 2023
Evaluation of Scores to Reflect Toxicity Impact on Quality of Life of Patients With Platinum-Resistant Ovarian Cancer: AURELIA SubstudyJustine Lequesne, Florence Joly, Julien Peron, et al.
Bulletin Du Cancer|June 6, 2012
[Safety and efficacy of bevacizumab combined with taxanes in the first-line treatment of metastatic breast cancer: ATHENA study-France]Anne-Claire Hardy-Bessard, Rémy Delva, Xavier Pivot, et al.
The British Journal of Radiology|January 24, 2024
Paediatric radiotherapy in the United Kingdom: an evolving subspecialty and a paradigm for integrated teamworking in oncologyAmy Colori, Raymond Ackwerh, Yen-Ch'ing Chang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2017
Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m<sup>2</sup>) and the Currently Approved Dose (25 mg/m<sup>2</sup>) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICAMario Eisenberger, Anne-Claire Hardy-Bessard, Choung Soo Kim, et al.
Pageof 11